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Abstract
In 1974, the “ariadne’s thread” (from greek mythology, pick one’s way through the 
labyrinth) of autoimmunity leading to the immunogenetic theory of type 1 diabetes 
mellitus made it possible to conclude that in this phenotype there exists an unsolved 
conflict between β-cells and the body’s autoreactive immune system.  In type 2 dia-
betes mellitus (T2Dm), the “ariadne’s thread” links obesity to pancreatic β-cell biology. 
unfortunately, beginning from a wrong interpretation of the relationship between 
plasma glucose and plasma insulin, the insulin resistance hypothesis was born and 
claimed as the main defect of T2Dm.  Overlooking obesity, the understanding of T2Dm 
pathogenesis was delayed by almost half a century. Fortunately, the adipobiology, par-
ticularly adipocytes was able to reach the “drawing board” of researchers, and has all 
the chances these cells to become the “cell of the century,” just as the pancreatic β-cell 
was last the cell of century. The association of diabetes and obesity has motivated us 
to put pancreatic β-cells and adipocytes head-to-head, that is, we moved from the 
T2Dm-obesity couple to the β-cell-adipocyte couple, appreciating their main secretory 
products, insulin/proinsulin, c-peptide, amylin (for β-cells), and adiponectin, as well as 
other numerous adipokines (for adipocytes). We thus propose that the proinsulin-to-
adiponectin ratio could become the earliest predictor of dysfunction of these two cell 
types.
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Knowledge means 
to know the cause.
Aristotle of Stagira 
(348-322 BC)
The knowledge of disease means 
the knowledge of its cause.
Paulescu of Bucharest 
(1869-1931)
introduction
The association between diabetes 
and obesity (recently termed “di-
abesty”) has been known for a long 
time.  Lancereaux in 1877 made the 
distinction between “fat” diabetes 
and “lean” diabetes (1,2).  Along with 
other researchers (2-4), we also have 
approached this “old couple” (3), 
documenting that this association is 
related to the degree of obesity and 
also with its duration.  About 90% of 
10 000 cases of newly diagnosed dia-
betes analyzed by us were overweight 
or obese (5).  In an interesting study 
by Sims and Horton (6) carried out 
on normal weight volunteers, they 
demonstrated that a hypercaloric diet 
leading to weight gain will show a pro-
portional increase in plasma insulin 
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levels.  However, soon after losing the acquired weight through 
food restriction, plasma insulin returned to previous basal lev-
els.  The relationship between body mass index (BMI) and insu-
lin is now well known (7-11) and can be explained by increased 
number of insulin dependent cells, rich in insulin receptors. It 
is obvious that such an enlarged adipose tissue will need higher 
amounts of insulin. However, such an increasing overload of 
function will become an important supplementary diabetogenic 
factor, aside from inherited diabetogenic architecture which can 
comprise some of the ~50 genes associated with diabetes (12).  It 
is important to know that adipose tissue is the only type of tissue 
which can increase by 3, 5, or even more times.
The increased insulin secretion observed in obese people has 
been considered as expressing an insulin resistance.  This way 
of thinking stemmed from the paper published by Yalow and 
Berson in 1960 (13) in which their results were reported regard-
ing blood glucose and plasma insulin assessment in diabetic 
patients and in normal (control) subjects, both in fasting state 
and after stimulation with 100 g or 50 g of glucose intake.  Over-
looking the plasma glucose levels, evidently higher in diabetic 
patients than in controls, they suggested that “maturity-onset” 
diabetics, the actual type 2 diabetes mellitus (T2DM), are “hy-
perinsulinemic.” Of course, after making a correction for insulin 
plasma levels versus blood glucose, such hyperinsulinism does 
not exist. Rosalyn Yalow (13) was an expert in nuclear physics 
and Solomon Berson (13) a medical thinker, but not a medical 
practitioner.
After the Nobel Prize in Physiology of Medicine was awarded 
in 1978 to Rosalyn Yalow for remarkable achievements in dis-
covering the radioimmunologic method for the assessment of 
insulin and later for other hormonal biological compounds (Sol-
omon Berson died in 1972), their data referring to the hyperin-
sulinism recorded in newly diagnosed diabetic patients resulted 
in a way of thinking that went in the wrong direction.  This oc-
curred because of a lack of minimal clinical data (age and BMI, 
for instance), which is an absolute requirement for correct inter-
pretation of insulin levels.  In this context, the idea was promoted 
that the first defect in diabetes is an insulin resistance somewhere 
in the body and the normal β-cell will react by inducing a hy-
persecretion of insulin (hyperinsulinism) in order to overcome 
the supposed insulin resistance.  During the long-term strug-
gle of the β-cell with this mysterious insulin resistance, β-cells 
will progressively decline, leading ultimately to total failure.  It is 
amazing to behold today how the wrong interpretation of some 
abnormal biochemical data can be so ingeniously muddled, 
based on some logical supposition, and supported mainly by nu-
merous and complicated investigations, such as the “euglycae-
mic-hyperinsulinemic clamp” of De Fronzo (14), the “minimal 
model” of Bergman et al (15), followed by what we have termed 
a “mathematical euphoria” (16) which has borne many tens of 
indices for insulin resistance-sensitivity-disposition index, re-
sulting from elaborate mathematical formulas.  Such an “aura 
of elevated science” is imposing for any practitioner, leaving the 
impression that this phenomenon does indeed exist.  However, 
some clinicians conclude that similar useful information could 
be obtained by such sophisticated methods can result simply 
from abdominal circumference measurements (17).
In 1985, Matthews et al (18) put fasting plasma glucose and 
insulin in a formula, resulting in what is called the Homeostasis 
Model Assessment (HOMA)-IR (insulin resistance), the most 
commonly used index of insulin resistance in epidemiological 
research.  Because plasma insulin levels increase with increasing 
body weight, almost all overweight/obese patients are character-
ized as insulin resistant.  Such a characterization is also made 
when a β-cell defect results in hyperglycemia.  In order to make 
a distinction between the two components, sensitivity to insu-
lin/ β-cell defects, a new formula called HOMA-B was devel-
oped, offering unconvincing information.
The insulin resistance hypothesis reached its climax in 1988 
(19) when Gerald Reaven published his observation leading to 
the concept of metabolic syndrome.  For a short period of time, 
this syndrome was also called “insulin resistance syndrome” 
(16).  After a re-evaluation of this concept (20-25) in the Edito-
rial in Diabetologia (25), the eulogy given by Borch-Johansen 
wishing insulin resistance syndrome “rest in peace” seems to 
be rather premature, even if this “phantom concept” reemerges 
from time to time once in a blue moon.  I predict that what is 
Caesar’s will be rendered unto Caesar, and what is attributed to 
insulin resistance will be given to obesity.
the pancreatic β-cell-adipocyte couple
Now, let us move from the T2DM-obesity couple to the pancre-
atic β-cell-adipocyte couple. The system which ensures energy 
homeostasis of the human body is very complex and includes 
several hypothalamic nuclei and limbic system, with their com-
plex orexigenic and anorexigenic pathways influencing alimen-
tary behavior and food intake.  A more complex behavior in-
volving the cerebral cortex also influences the degree of physi-
cal activity and levels of energy utilization.  The disequilibrium 
between food/caloric intake (increased) and physical activity 
(decreased) is promoted by the actual lifestyle which explains 
stepwise increase in overweight, obesity and T2DM. When such 
disequilibrium appears, all the components of the energy system 
react in order to adjust the inactivity according to the new bio-
chemical reality.  
The most important subsystem is adipose tissue with its im-
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pressive capacity to process and store high to very high amounts 
of lipids.  Its role as a “buff er” system is one of its main metabolic 
functions.  Ancestrally, its secretory function was adapted more 
to conserve energy.  Th is is why adiponectin secretion mainly in 
the omento-mesenteric compartment (26) has a role of optimiz-
ing the utilization of fatty acids in various organs (liver, skeletal 
muscle, pancreatic β-cells), maintaining their normal function. 
Unfortunately, adipocyte function in overweight and obese 
conditions, our genetic makeup which was not programmed 
to waste but to conserve energy, and as such, will inherently 
counteract any attempt in weight reduction, except through the 
energy consumed by skeletal muscles during physical exercise. 
Alas, modern imprudent socio-economic patterns which lead to 
increasingly sedentary lifestyles place the adipocyte in an ines-
capable dilemma.
What about the pancreatic β-cell?  Th is veritable “metabolic 
brain” is asked to solve a challenging pathologic condition that 
is, in fact, unsolvable, in which there exists a large amount of fat 
accumulation in obese individuals, not only in a protected form 
(inside adipocytes), but also outside this tissue as ectopic fat de-
posits, sometimes intracellular and other times extracellular.  It 
must compensate for this additional fatty mass secreting more 
and more insulin in less and less physiological circumstances.
the endoplasmic reticulum stress in pancreatic β-cells 
and adipocytes
Each nucleated cell, especially secretory cells (such as pancre-
atic β-cells and adipocytes) have a well developed endoplasmic 
reticulum (ER)-Golgi apparatus (GA) networks (Fig. 1A).  Here 
take place various post-translational modifi cations of transcripted 
preproproteins mediated by polyribosomes attached to ER sur-
face.  However, between pancreatic β-cells and adipocytes there 
are many important diff erences.  Th e pancreatic islets cells have 
all together a mass of ~1.5 g.  In each islet, there are ~5000 vari-
ous types of cells (α – glucagon secretion; β – insulin secretion; 
δ – somatostatin secretion; γ – pancreatic polypeptide secretion; 
Figure 1. a. an electron microscope 
image from a section of pancreatic 
β-cell showing the nucleus (left) and 
a well developed rough endoplasmic 
reticulum (right) with a few secretory 
vesicles present B. an electron micro-
scope image from a section of pancre-
atic β-cell showing numerous secretory 
vesicles. c. Electron microscopy from 
subcutaneous adipose tissue showing 
three adipocytes and stromal tissue be-
tween them and a capillary vessel (bc). 
D. section of a large adipocyte show-
ing the nucleus, endoplasmic reticulum 
and few mitochondria. Magnifi cation: 
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ε – ghrelin secretion), of which only ~3000 are β-cells, which se-
crete insulin, C-peptide, and amylin.  In contrast, the adipocytes 
number is enormous (~1.6 billion), weighing ~13 kg at a BMI of 
22 kg/m2 and 35 kg at a BMI of 35 kg/m2 (27), with  possibility to 
increase manifold in morbid obese subjects (BMI >45).
The ER is a proximal cellular site that is able to sense “bio-
chemical pressure” occasioned by fuel excess in the energy sys-
tem as well as react in a compensatory manner.  To function 
properly, the ER relies on numerous resident chaperone proteins, 
higher calcium content, and an oxidative environment.  Any 
perturbation in the function of this system may trigger accu-
mulation of unfolded proteins and activates a specific ER stress 
response, known as the “unfolded protein response” (UPR) (28). 
This reaction led either to the reestablishing of physico-chemical 
derangements or to the triggering of apoptosis of these cells.  The 
same model of reaction appeared in β-cells, where this mecha-
nism was better studied (29,30), but also in adipocytes (31,32), 
and later in hepatocytes and other insulin-dependent or even 
non-insulin-dependent cells.
The apoptosis of a cell is accompanied by an inflammatory re-
action, which in adipose tissue is very high due to large adipocyte 
volume. Any supplementary lipogenesis, in a large adipocytes is 
made with the price of apoptosis. That explained the proinflam-
matory reaction induced by the signals sent by large adipocytes 
such as through monocyte chemoattractant protein-1 (MCP-1), 
serum amyloid A3 (SAA3), retinol binding protein-4 (RBP-4), 
resistin, visfatin, vaspin, and others. These signal molecules are 
included in exosome-like structures which are multivesicular 
body (endosome)-derived microvesicles (50-100 nm), secreted 
in an oscillatory fashion through an exocytotic machinery act-
ing in adipocytes (33). Under healthy conditions, the human 
body is in a state of “controlled inflammation” regulated by a del-
icate balance of pro-inflammatory factors, e.g. tumor necrosis 
factor-alpha (TNF-α), leptin, interferon-γ, interleukin-1 (IL-1), 
IL-6, IL-12 and anti-inflammatory/metabotrophic factors, e.g. 
adiponectin, IL-10, NGF, BDNF, which may also be produced 
by adipose tissue cells including adipose-associated immune 
cells (macrophages, mast cells, T-lymphocytes) (reviewed in 34).
the pancreatic β-cell versus the adipocyte
It is worthy of note that many of the current uncertainties con-
cerning the function and dysfunction of these two cell types, the 
pancreatic β-cell and the adipocyte, are due to the disequilib-
rium between the information sources available.  Many come 
from studies carried out on animal models, in transgenic mice, 
in ex vivo cultured cells, and very few studies performed on hu-
man pancreatic and adipose tissue.
Few people are aware that the diameter of a large adipocyte 
(~200 μm) is equal to the total diameter of all pancreatic islets 
(~250 μm), in which ~5000 of various cells (α, β, γ, δ, and ε) are 
distributed.  We do not have data regarding the cumulated ER 
for a single pancreatic β-cell and for a single adipocyte, but that 
for β-cells might be larger and, probably, have a higher activity 
than their adipocyte counterparts (Fig. 1C, D).
The β-cell mass is generally programmed to produce an 
amount of insulin covering not only the needs of normal weight 
subjects, but also supplementary secretory capacity in order to 
cover the higher insulin needs in some physiological conditions 
(i.e., pregnancy), and also a higher amount of skeletal muscle 
cells (hard workers), or excessive fat deposits (in overweight or 
obese subjects).  Why such supplementary secretory overload 
can’t be covered in about 30% of the overweight/obese people 
is not well known. These are prone to developing T2DM and 
cardiovascular disorders during their lifetime.
the vulnerability of a marvelous cell
Among the 3 billion pancreatic β-cells, there is a large hetero-
geneity (35).  With its neuronal phenotype, the β-cell can react 
promptly and efficiently to all biochemical changes in concen-
trations of various fuels (carbohydrates, amino acids and fatty 
acids).  This refined dose/response reaction depends on the 
inclusion of insulin (its main secretory product) in small orga-
nelles called secretory vesicles (SV). These are, however, com-
plex and stable structures which appear in a nascent form in the 
ER-GA compartment where nascent vesicles are produced in 
tight correlation with the amount of exocyted SV. Upon looking 
at such a secretory β-cell, what is impressive is the high number 
of such SV (Fig. 1B). In their way, beginning from ER-GA to the 
last “ready to be released” compartment, the “immature” vesi-
cle became a “mature” vesicle in which up to 99% of proinsulin 
is cleaved into insulin and C-peptide, and insulin is stored in a 
concentrated form as hexameric insulin crystals which appears 
as an electron dense core of such vesicles.  Dispersed in the sur-
rounding cytosolic halo can be found, in a very acidic medium 
(pH 5–5.5), C-peptide, amylin, small amounts of proinsulin and 
proamylin, and enzymes, chaperones, Ca2+, Zn2+, and other ions, 
or other small molecules with unknown functions.
From the translation of the preproinsulin gene as a peptide 
of 110 amino acids, to their appearance as complex three di-
mensional mature insulin molecule takes approximately 4–5 h. 
From the ~12 000 SV continuously existing in a β-cell, only a 
small part are stored in a “ready to be released” compartment, 
close to the cell membrane.
In fact, the syntagma used by Orci 30 years ago, for β-cell as an 
“insulin factory” (36), can be better characterized as a “secretory 
vesicle factory”. No regulated secretion of insulin can be possible 
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without the inclusion of insulin in these fascinating organelles, in 
which each contain about 300 000 insulin molecules.  There is, 
however, a high price for this refined structure and function.  In 
adults, these cells are post-mitotic cells, and neogenesis is either 
very low or (especially in diabetic patients) completely absent 
(37). In such a condition, we can state that the onset of diabetes 
is the moment when an apoptosed β-cell cannot be replaced with 
a new one.  Fortunately, β-cell loss occurs very slowly, in that for 
the decompensation of blood glucose regulation (onset of clinical 
diabetes) this process may take years, even tens of years.  This is 
why the highest incidence of T2DM is around the age of 60 years. 
By the time diabetes is diagnosed, about 50% of β-cell mass/func-
tion has already been irreversibly lost.  It is obvious that diabetes 
starts earlier, and when hyperglycaemia appears, what we must do 
is to prevent the severe chronic complications of diabetes, to nip 
them in the bud ahead of time.
the diabetogenic role of adipose tissue
The good news is that not all obese people develop diabetes, only 
30%.  The bad news is that in our days, in an increasing number 
of individuals, diabetes onset appears at younger ages than be-
fore (27).  This higher number of new cases of diabetes is recruit-
ed especially from overweight and obese children, adolescents 
or young adults (27).  If our aim is to stop this diabetic trend, we 
must prevent obesity, acting in each growth and developmental 
period, with preventable lifestyle interventions. So, nowadays, 
the main goal is to detect diabetes when the first diabetogenic 
mechanisms begin.  Hyperglycemia must remain an important 
parameter, but we must replace it with new and earlier indicators 
of the functional disequilibrium between pancreatic β-cells and 
the adipocytes.  Recent data demonstrate that the neurotrophins 
nerve growth factor (NGF) and brain-derived neurotrophic fac-
tor (BDNF) are produced by peripancreatic adipose tissue and 
might be involved in the regulation of insulin secretion as well 
as the pathogenesis of metabolic syndrome and T2DM (38, also 
see Hiriart et al in this issue of Adipobiology).
We will attempt to demonstrate that β-cell and adipose tissue 
dysfunction must be reflected in the level of plasma proinsulin 
and adiponectin.
Visceral versus subcutaneous obesity
Classically, visceral obesity was considered much more patho-
genic than subcutaneous obesity (39-42).  Is the visceral (omen-
to-mesenteric) compartment more pathogenic than subcutane-
ous adipose tissue?  A conclusive response to this question is 
impossible in the present time. Contrary to what is currently 
accepted that visceral adipose tissue is pathogenic and subcuta-
neous adipose tissue is protective, we can provide some physi-
ological arguments in favor of normal function of omento-mes-
enteric adipose tissue. First, the visceral adipose tissue expresses 
more adiponectin, a potent anti-inflammatory and anti-diabetic 
adipokine, than any other adipose compartment (26) and ex-
presses less pro-inflammatory adipokines (26).  Also, it is possi-
ble that adipocytes from omento-mesenteric compartment have 
a lower turnover than adipocytes from abdominal subcutaneous 
tissue. From this point of view, the visceral adipose tissue could 
have a greater role as an endocrine, adiponectin-secreting organ 
compared to a metabolic role (as a buffer system for fatty acids) 
of subcutaneous adipose tissue; adiponectin secretion decrease 
reflects its severe dysfunction.
Silent, restless, and aggressive adipose tissue
In the classification recently proposed by one of us (16), adipo-
cytes can pass through three different functional/dysfunctional 
phases: the silent (quiet) adipocyte; the restless adipocyte; and 
finally, the aggressive adipocyte.  The notion of the silent adipo-
cyte corresponds the physiological activity which the adipocyte 
carries out in a clinically unnoticeable way. The crosstalk of ady-
pocites with all other cells belonging to the “energy administra-
tion system” of the human body which works precisely.
The notion of the restless adipocytes corresponds to the pro-
duction of many helper signals sent to circulating monocytes 
(via MCP-1), which accumulate in dysfunctional adipose tissue 
(e.g., in hypoxia due to the discordance between angiogenesis 
and adipogenesis), or by the increasing diameter of hypertro-
phied adipocytes, exceeding the oxygen diffusion capacity in 
their deeper stratum.
The adipocytes (in fact, adipose tissue) become aggressive in 
subjects with a higher degree of obesity (BMI >40), and many 
apoptosed adipocytes attract a high  number of macrophages 
which surround the dead adipocytes, giving a “crown-like” 
appearance. These macrophages also produce numerous adi-
pokines such as TNF-α, IL-6, IL-10, RBP-4, resistin, visfatin, 
vaspin, which through the systemic circulation induce the so-
called low-grade inflammation status.  In this condition, adi-
ponectin production decreased, and that heralded the onset of 
T2DM and cardiovascular disease. 
The importance of this pathophysiological classification of 
adipose tissue, whose characteristics are listed in Table 1, have 
two goals:  (i) it permits a better understanding of the etiopatho-
genesis of T2DM associated with obesity, and (ii) to use some 
of the adipocyte’s molecular markers for earlier identification 
of active diabetogenic mechanisms, which sometimes precede 
from years to decades the irreversible decompensation of blood 
glucose regulation.
An important factor in the progression from the silent to the 
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restless stage is the increased volume of adipocytes from ~300 
picoliters to ~750 and then to 1000 picoliters (43-45), which 
corresponds to an increase in adipocyte diameter from 90 μm 
(in silent adipocytes) to 120 μm and then over this value (“giant 
adipocytes”), in restless or aggressive adipocytes.
Diagnostic markers for early stage of diabetes
Following our previous studies, we proposed for the detection 
of early phase of diabetes the proinsulin-to-insulin ratio (46-51). 
Th e latter is increased in all phenotypes of diabetes (Fig. 2), even 
in prehyperglycaemic stages and in obesity, heralding the future 
decompensation of blood glucose regulation.  However, both of 
these parameters, insulin and proinsulin, refl ect the same defect 
in β-cell function following the above mentioned defect in the 
cleavage of proinsulin to insulin and C-peptide, indicating a de-
fect in maturation of the SV (52).
Recently, Giannini et al (53) performed an interesting study 
on adolescent obese subjects including 1600 Caucasians, Afro-
Americans and Hispanic youths. All subjects underwent a single 
oral glucose tolerance test (OGTT) and 80.2% were normal glu-
cose tolerant (NGT) according to classical defi nition of normali-
ty: fasting plasma glucose <100 mg/dl and 2-h glucose <140 mg/
dl; 18.8% were IGT (>139 mg/dl but <200 mg/dl at 2h). Th en, 
60 NGT subjects were divided in two subgroups according to 





adiponectin normal Decreased  Decreased 
leptin normal or  Increased  Increased 
Rbp-4 normal Increased  Increased 
Il-10 normal Decreased  Decreased 
TnF-α normal Increased  Increased 
Il-6 normal Increased  Increased 
Resistin normal Increased  Increased 
visfatin normal Increased  Increased 
progranulin normal Increased  Increased 
*based on information from various published sources.
Rbp-4, retinol binding protein-4; TnF-α, tumor necrosis factor-alpha; Il-10, interleukin-10.
table 1. The main characteristics of silent, restless and aggressive adipocytes
Figure 2. plasma proinsulin levels in various subgroups of 
T2Dm patients versus controls. ns, not signifi cant, *p<0.05, 
**p<0.01 versus controls (from ref. 49).
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120-139 mg/dl. An additional 21 IGT group was also included. 
Th ese 4 groups were also evaluated two years later. Th e authors 
sought to determine whether obese adolescents with high “nor-
mal” 2-h post OGTT present or not some pathologic signals. A 
very careful investigation was made with both basal/static meth-
ods (determining many careful anthropometric and biochemi-
cal parameters, including proinsulin and adiponectin levels) and 
dynamic state-of-art techniques (hyperglycaemic-euglycaemic 
clamp and hyperglycaemic clamp) in order to detect earliest de-
fects in insulin secretion and sensitivity to insulin. Th ey found 
that fi rst phase insulin secretion decreased across NGT catego-
ries, but second phase insulin secretion was similar across all 
NGT and IGT groups. Also, the disposition index (cDI, which 
results from glucose disposal x sensitivity fi rst phase insulin se-
cretion) decrease across categories. Th is last parameter can be a 
summing up of the fundamental defects involved in T2DM: in-
sulin secretory defect and a decrease in peripheral glucose uptake.
Th e same information referring to the both dysfunction (in 
the β-cells and adipocyte cells) results from the ratio between 
plasma proinsulin (an indicator of β-cell dysfunction) and plas-
ma adiponectin (an indicator of adipocyte dysfunction). From 
Figure 3, on the base of our 300 studied cases (172 M/188 F, 
divided in normal weight controls, overweight, non-diabetic 
obese and obese diabetic) result a clear increasing ratio start-
ing from normal weight subjects to normoglycaemic overweight 
and to a highest ratio in hyperglycaemic obese patients. 
In order to check if our data are valuable, in Figure 4 we had 
showed the proinsulin-to-adiponectin ratio using the data pre-
sented by Geannini’s group in their paper (53). Th e proinsulin-
to-adiponectin ratio appears in the upper part (A) of the fi gure, 
whereas in the bottom part (B) is given the composite cDI index. 
Indeed the ratio proinsulin-to-adiponectin mirrors cDI and in-
dicates a dysfunction in both β-cell and peripheral tissues. Th e 
clearer information obtained from proinsulin-to-adiponectin 
ratio in our patients (Figure 3) vs. the same ratio in Geannini’s 
paper (Figure 4A) can be explained by the higher patient’s age in 
our groups than their group including adolescent subjects 
In fact, this state-of-the-art technique supports the validity of 
the proinsulin-to-insulin ratio. Th e contribution of an increased 
ratio (an increase in proinsulin, or a decrease in adiponectin) 
might give us a clue for better understanding the contributions 
of the individual dysfunction of these two important cell types.
It is obvious that such an elegant investigation carried out by 
Giannini et al (53) which are laborious, costly and time-consum-
ing is not destined for clinical practice. Instead what we propose 
is to obtain in a single blood glucose sample as much diagnostic 
information as possible from several essential determinations 
such as glucose and HbA1c (routinely used) and, additionally, 
Figure 4. The parallels between information given by the 
proinsulin-to-adiponectin ratio (a) and from the cDI (resulting 
from glucose disposal x sensitivity fi rst phase insulin secre-
tion) (B). see text for explanation.
Figure 3. cumulative data regarding proinsulin-to-adiponec-
tin ratio obtained in various categories of nondiabetic and 
diabetic overweight and obese subjects: 60 normal weight; 
80 overweight; 75 nondiabetic obese; 120 obese diabetic.
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plasma insulin, proinsulin and adiponectin. Otherwise in a re-
cent commentary published in Diabetes, Kulkarni (53) under-
lines the urgent need for identification of useful biomarkers for 
early phases of diabetes. Our efforts, is inline with this purpose. 
Using the information obtained through individual analysis of 
few hormonal parameters, we can also obtain not only diagnos-
tic, but supplementary pathogenic information, such as HOMA-
IR and HOMA-B, as well as the proinsulin-to-insulin (48-51) 
and proinsulin-to-adiponectin ratios.
For a large clinical utilization of such parameters, the main 
current barrier is the cost of proinsulin and adiponectin deter-
mination.  However, by a large usage in clinical practice their 
cost may rapidly decrease. If the value of our ratios will be con-
firmed in prospective populational studies, then very soon, a 
new classification of diabetes (regarding their staging) will be 
necessary. Such a classification requires a change in the criteria 
for definition of diabetes, replacing hyperglycaemia (the current 
diagnostic criteria) with earlier indicators of β-cell/adipocyte 
dysfunction. In fact, we are trying to change the epiphenomenon 
hyperglycaemia with phenomenon itself which is the progressive 
decrease in β-cell mass/function. In present, diagnosis of diabe-
tes based on hyperglycaemia detects only those cases in which 
> 50% of β-cell mass/function has already been irreversibly af-
fected (54, 55).
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